Number of shares and voting rights of Innate Pharma as at December 2, 2013
Innate Pharma raises €20.3 million in a private placement subscribed entirely by US-based specialist investors
Innate Pharma has launched a private placement to raise about 18 millions euros
Innate Pharma initiates IPH43 program to develop «first-in-class» anti-MICA antibody
Preclinical data opening new perspectives for development of lirilumab in combination to be presented at ASH
Three posters on the anti-KIR program to be presented at the upcoming ASH annual meeting
Launch of IND-Enabling studies for IPH4102
Innate Pharma announces revenue for the first nine months of 2013 and updates on its cash position
Innate Pharma presents proprietary antibody-drug conjugate technology at the World ADC Summit in San Francisco
Innate Pharma appoints Nicolai Wagtmann Chief Scientific Officer
